News on the Division of Lung Diseases
|
Statement
Findings from a randomized, non-blinded, phase 3 clinical trial supported by the National Institutes of Health found no significant difference in 90-day mortality rates, nor safety concerns, after providing patients with one of two common treatment strategies for sepsis. The findings were published in the New England Journal of Medicine and were...
|
NHLBI in the Press
Inhaled particles from air pollution accumulate in lung-associated lymph nodes and weaken immune defenses over time.
|
Research Feature
More than 15 million Americans live with chronic obstructive pulmonary disease (COPD), a progressive lung condition that makes it difficult to breathe. But monitoring the often-debilitating condition can be challenging. And when dangerous flare-ups go undetected — something that happens in at least half the cases — the result can be fatal...
|
Research Feature
For years, the community of researchers that studies sleep has tried to raise awareness about the growing link between poor sleep and heart disease. Now, after much effort, they can mark progress toward recognizing that all-important connection. For the first time, the American Heart Association has added sleep to the key components it advises...
|
News Release
Adults who cut back on sleep for six weeks had increased markers of inflammation Getting a consistent good night’s sleep supports normal production and programming of hematopoietic stem cells, a building block of the body’s innate immune system, according to a small National Institutes of Health-supported study in humans and mice. Sleep has long...
|
News Release
About 20–40% of adults with COPD symptoms but who aren’t diagnosed with COPD use these types of long-lasting inhalers Researchers supported by the National Institutes of Health have found that dual bronchodilators – long-lasting inhalers that relax the airways and make it easier to breathe – do little to help people who do not have chronic...
|
NHLBI in the Press
An experimental anticancer drug called saracatinib shows promise as a treatment for Idiopathic Pulmonary Fibrosis (IPF), a chronic and often fatal condition that causes scarring or fibrosis of the lungs.